2024-516338-37-00
已完成
1 期
A phase Ib study to investigate the safety and effect of BR-003
SentryX B.V.1 个研究点 分布在 1 个国家目标入组 6 人2024年8月9日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- SentryX B.V.
- 入组人数
- 6
- 试验地点
- 1
- 状态
- 已完成
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
Jorrit-Jan Verlaan
Scientific
SentryX B.V.
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
未指定
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44
招募中
不适用
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001NCT07264569Henan Cancer Hospital42
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
招募中
1/2 期
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects with advanced solid tumors that cannot be removed with surgery or has spread locally or to other parts of the body.2023-505334-10-01Marengo Therapeutics Inc.46
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18